Navigation Links
Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
Date:10/27/2009

28,536 4,691 23,195 27,886 ----- ------ ------ ----- ------ ------ Oncology 58,542 24,526 83,068 29,242 23,195 52,437 Other 6,632 37,382 44,014 11,351 35,000 46,351 ------- ------ ------ ------ ------ ------ $440,418 $94,805 $535,223 $396,938 $92,726 $489,664 ======== ======= ======== ======== ======= ======== % Increase (Decrease) ---------- United States Europe Total ------- ------ ----- Net sales: PROVIGIL -% (6%) -% NUVIGIL - - - GABITRIL (5) (43) (11) CNS 8 (10) 7 ACTIQ (8) (5) (7) Generic OTFC (1) - (1) FENTORA (13) - (11) AMRIX 30 - 30 Pain (1) 3 (1) TREANDA 122 - 122 Other (15) 6 2 Oncology 100 6 58 Other (42) 7 (5) 11% 2% 9% Nine Months Ended September 30, ------------- 2009 2008 ---
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   Regulus Therapeutics ... biopharmaceutical company leading the discovery and development of ... initiated its ATHENA natural history of disease study ... kidney disease with no approved therapy. The ATHENA ... of renal function markers such as Glomerular Filtration ...
(Date:9/18/2014)... , Sept. 18, 2014 Just days before ... a three-day quarantine to contain the spread of Ebola, World ... medical relief supplies – thanks to private donations. ... United States , through its affiliate McKesson Medical-Surgical donated ... the entire country of Sierra Leone,s ...
(Date:9/17/2014)... Sept. 17, 2014 North America Gynecological ... GlobalData,s new report, "North America ... market data on the North America Gynecological Devices ... US dollars, volume (in units) and average prices ... Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3
... Bias, DURHAM, N.C., Sept. 15 Less ... treatment are eventually published in,medical journals, according to ... Oncologist.", (LOGO: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO ), ... of Washington and,Fred Hutchinson Cancer Research Center, Seattle, ...
... a novel ... macrolide-related drug class, WATERTOWN, Mass., Sept. ... molecule anti-infective drugs, announced,today the initiation of a Phase 1 ... novel,macrolide-related drug class with a distinct resistance profile. The,clinical development ...
Cached Medicine Technology:Most Cancer Treatment Studies Aren't Published, Study Finds 2Most Cancer Treatment Studies Aren't Published, Study Finds 3Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 2Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 3
(Date:9/18/2014)... 2014 Pathways Home Health & ... position of Chief Medical Director. Prior to accepting ... Pathways programs including Pathways KIDS, adult palliative care, and ... and Santa Clara Counties. , In her new ... Pathway’s patient care program. She will supervise five medical ...
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Imaging technology has ... stress disorder (PTSD) manifest in the brain, according to ... health condition that can cause a wide range of ... being in a constant state of stress and avoiding ... the study. Researchers identified a specific opioid receptor ...
(Date:9/18/2014)... 2014 -- Only about half of all pregnant women ... thousands of moms-to-be and their babies at increased risk of ... be a routine part of prenatal care," said Edward McCabe, ... should offer their pregnant patients a flu shot each year ... , A report by the U.S. Centers for Disease Control ...
(Date:9/18/2014)... in disadvantaged neighborhoods have worse musculoskeletal pain outcomes ... vehicle collision than individuals from higher socioeconomic status ... as age, sex, income, education, and employment status. ... research study led by Samuel McLean, MD, MPH, ... the University of North Carolina School of Medicine. ...
(Date:9/18/2014)... COPENHAGEN, Denmark and CAMBRIDGE, Massachusetts, U.S.A., September 18, ... Tech) is providing sequencing service to Denmark-based DLF-Trifolium ... (MBG) at Aarhus University in an effort to ... varieties by employing genomic selection (GS) methods. , ... selection, which in contrast to the traditional QTL-based ...
Breaking Medicine News(10 mins):Health News:Dr. Ellen Brown Promoted to Chief Medical Director at Pathways Home Health & Hospice 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 3Health News:Flu vaccine for expectant moms a top priority 2Health News:Living in a disadvantaged neighborhood worsens musculoskeletal pain outcomes after trauma 2Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2
... anti-HLA antibody assays both contribute to characterization ... ... immunosuppression, COLUMBIA, Md., June 1 Data developed by Cylex ... the American Transplantation Congress in Toronto, Canada, suggest,that cell-mediated immunity and ...
... also helped with severe fatigue among patients on chemotherapy ... the more common and unpleasant side effects of treatment ... by the ancient Chinese practice of acupuncture. , A ... and pain and shoulder dysfunction after neck dissection in ...
... treatment of choice for advanced, metastatic prostate cancer has ... testosterone the hormone that fuels prostate-cancer growth ... drugs. While such therapy buys time for patients, it ... resistant to the androgen deprivation and continues to grow. ...
... VA Three new studies published in the June ... focus on what role gender plays in the prognosis ... and the success rates of hearing aid implants in ... the wide variety of critical research being undertaken every ...
... pancreatic, kidney cancers, respectively , , SATURDAY, May ... cancer -- which historically carries a grim prognosis ... cancer drug Gemzar was used after surgery, new ... of pancreatic cancer patients are even candidates for ...
... death for female survivors; cardiovascular events for males ... survived Hodgkin lymphoma as children have an increased risk ... disease as adults, according to a new report. ... -- may help drive these increased risks, according to ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 2Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New research offers insight into oral cancer, chronic pediatric ear infections, and hearing health 2Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Hodgkin Lymphoma Kids Face Greater Risk of Future Problems 2
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... ADx pacemaker family, which ... dual-chamber pacemaker, provides clinicians ... including the revolutionary AF ... U.S. commercially approved algorithm ...
... ADx pacemaker family, which includes ... provides clinicians with the most ... the revolutionary AF Suppression™ algorithm, ... commercially approved algorithm designed to ...
Medicine Products: